Strategic Partnerships PharmaJet is actively pursuing collaborations with regional public health and vaccine delivery programs, including AFENET for fIPV delivery in Nigeria and EVA Pharma in Egypt, presenting aligned growth opportunities in emerging markets with needle-free delivery solutions.

Needle-Free Expansion The company is expanding its needle-free delivery portfolio into self-injector pens for chronic disease and metabolic peptide markets, signaling potential cross-sell paths to healthcare providers, clinics, and patient populations seeking anxiety-reducing, convenient administration.

Immunization Focus With FDA clearance for Stratis and CE/PQS certifications for Tropis, PharmaJet has validated, globally deployable platforms suitable for routine immunization programs, enabling sales targeting national immunization initiatives and international procurement programs.

Global Market Readiness Active participation in industry events and partnerships (BIO 2025, PODD, WVC presentations) indicates a market-facing strategy to attract distributors, government buyers, and large immunization programs seeking modern delivery technologies.

Financial Growth Signals Current revenue range and substantial funding runway (revenue $1M-$10M; funding $44M) suggest capacity for scaled production, expanded sales teams, and targeted go-to-market investments in high-potential regions and institutional buyers.